[Antidepressants and suicide in adolescents].
ABSTRACT In recent years, drug regulation agencies from the US and the UK have issued warnings concerning the emergence of suicidal behavior in children and adolescents treated with antidepressants. As suicidal behavior is the most feared of the core symptoms of depression, these warnings were naturally met with great concern by mental health care technicians and afflicted patients and families. In this article we have conducted a review of the literature discussing the controversy that originated in 2003 with the reanalysis of data from clinical trials with selective serotonine reuptake inhibitors. Following our review of meta-analyses, observational studies and ecological studies, we found that SSRIs show some efficacy and are generally safe in the treatment of adolescent depressive disease, provided that the clinical decision to prescribe them is properly weighed and discussed. We make some clinical recommendations, underscoring that adolescents who are medicated with antidepressants must be carefully monitored with regard to suicidal behavior and eventual adverse effects.
- SourceAvailable from: Francisco Javier Bonilla Escobar[Show abstract] [Hide abstract]
ABSTRACT: To compare the incidence of adverse events between active and placebo arms of randomized clinical trials in depressive children and adolescents (C&A) with antidepressant treatments, in order to look for similarities in both groups that allow to establish a possible nocebo effect. Systematic search strategy (January 1974-March 2013) in electronic databases, conference abstracts, and reference list of systematic reviews and included studies to identify parallel randomized placebo-controlled trials of antidepressants in C&A (<19 years) with major depressive disorder, and one or more interventions of any orally administered antidepressant. The pooled adverse events were calculated based on a fixed-effect model and statistical analysis involved the risk ratio (RR) of adverse events, with 95% confidence intervals (95% CI). Sixteen studies were included in the review, of which seven studies with a sample of 1911 patients had data to include in the meta-analysis. There was similar risk for the incidence of adverse events between non-active and active group (global RR 1.04, 95% CI: 0.97-1.11). Depressive C&A allocated to placebo or active group had similar risk to develop adverse events. These similarities in both groups are attributed to the nocebo effect. It is of note that defining "nocebo" effects is challenging in clinical populations because adverse effects may be attributed to the intervention or may be manifestation of the disease itself. The inclusion of a no-treatment arm may be warranted. Nocebo effects are likely when adverse events of placebo mimic the adverse events of active treatment, as was the case here.Frontiers in Behavioral Neuroscience 11/2014; 8:375. DOI:10.3389/fnbeh.2014.00375 · 4.16 Impact Factor